Resistance to Novel β-Lactam–β-Lactamase Inhibitor Combinations

Significant advances were made in antibiotic development during the past 5  years. Novel agents were added to the arsenal that target critical priority pathogens, including multidrug-resistant Pseudomonas aeruginosa and carbapenem-resistant Enterobacterales. Of these, 4 novel β-lactam–β-lactamase inhibitor combinations (ceftolozane-tazobactam, ceftazidime-avibactam, m eropenem-vaborbactam, and imipenem-cilastatin-relebactam) reached clinical approval in the United States. With these additions comes a significant responsibility to reduce the possibility of emergence of resistance. Reports in the rise of resistance toward ceftolozane-tazobactam and ceftazidime-avib actam are alarming. Clinicians and scientists must make every attempt to reverse or halt these setbacks.
Source: Infectious Diseases Clinics of North America - Category: Infectious Diseases Authors: Source Type: research